Vaccine generates durable immune responses in people at high risk for pancreatic cancer Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops. Written byAndrea Corona

Vaccine generates durable immune responses in people at high risk for pancreatic cancer Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops. Written byAndrea Corona https://www.drugdiscoverynews.com/vaccine-generates-durable-immune-responses-in-people-at-high-risk-for-pancreatic-cancer-17365?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--kLSTjOl2-5yLrwYxQvdbgb_wt2C9NFXdHV0LM3qWqQlAxVxL0NgBOB30vvqo9iA1tMuQFrGMcN2vmpyo8FiiRs7hf3w&_hsmi=437947290&utm_content=437947290&utm_source=hs_email Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest five-year survival rates of any cancer, in large part because it is rarely caught early. Most cases are diagnosed at advanced stages, when surgery is no longer an option and systemic treatment options remain limited. For the roughly 10 percent of cases driven by hereditary predisposition, high-risk individuals are currently managed through surveillance — watching and waiting for signs of transformation into cancer with few tools to intervene before that happens.